article is a commentary written by Hannelore Ehrenreich, a neuroscientist at the Max Planck Institute for Experimental Medicine in Goettingen, Germany. Dr. Ehrenreich emphasizes the clinical need for non-erythropoietic tissue protective compounds, especially for chronic treatment of neurological and psychiatric conditions. She writes: "Any step forward in treatments for stroke, acute brain or spinal cord injury, or for chronic neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, or diabetic neuropathy, would be a major contribution to medicine."

'"/>

Contact: Betsy Abrams
babrams@warrenpharma.com
914-762-7586
Warren Pharmaceuticals, Inc.
8-Jul-2004

Page: 1 2 3
Related biology news :

1. Cyclis Pharmaceuticals reports studies defining new mechanism for potential cancer therapies
2. Final results of the two Zevalin pivotal trials in radioimmunotherapy for B cell Non-Hodgkins Lymphoma announced by IDEC Pharmaceuticals
3. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
4. Idun Pharmaceuticals Identifies Cell Type And Molecular Pathway Involved In TransplantationRelated Liver Damage
5. Cubist Pharmaceuticals Describes New VITA™ Technology For Enabling Genomics For Drug Discovery
6. Vertex Pharmaceuticals/Yale Research Team Uses Gene Knockout Mice To Establish Role Of Caspase-9 In Neuronal Cell Death Pathway
7. Scientists At The Scripps Research Institute And R.W. Johnson Pharmaceuticals Develop New Antibacterial Agents
8. Vertex Pharmaceuticals Researchers Report Three-Dimensional Structure Of Hepatitis C Helicase Enzyme; Report In Structure
9. Pharmaceuticals Manufactured In Insect Larvae
10. Wiley publishes Welcome to the Genome: A Users Guide to the Genetic Past, Present, and Future
11. Professor publishes book on historic mosquito wars